DIAGNOSING SUBSETS OF TRIPLE-NEGATIVE BREAST CANCER

摘要

The present invention provides a unique combination of biomarkers that identify triple-negative breast cancer (TNBC) patient subpopulations. Such subpopulations will have differential responses to therapies, and thus treatments can be tailored to particular patients.

主权项

1. A method of classifying a subject with triple-negative breast cancer (TNBC) or and BRCA1-related breast cancer as having an active or inactive 53BP1 degradation pathway comprising:
(a) obtaining a sample from said subject comprising tumor cells; and (b) assessing nuclear protein levels of 53BP1, cathepsin L (CSTL) and vitamin D receptor in said tumor cells, wherein if (i) the patient has high CTSL, low 53BP1 and low VDR, the 53BP1 degradation pathway is active, (ii) the patient has high CTSL, high 53BP1, and high VDR, the 53BP1 degradation pathway is inactive, and (iii) the patient has low CTSL and low 53BP1, the 53BP1 degradation pathway is inactive and the 53BP1 gene contains a mutation or the transcript is destabilized.